UAE-based Julphar Gulf Pharmaceutical Industries has announced the appointment of the company’s associate director finance, Laurent de Chazeaux, as acting chief financial officer – effective immediately.

He replaces Jerome Carle, who has been promoted as the general manager of Julphar.

As acting CFO, de Chazeaux will be responsible for leading the company’s finance department and keeping accurate financial records. He will be in charge of the administrative and risk management operations and will develop financial strategies in line with Julphar's objectives.

He will report to the company’s general manager Jerome Carle.

On the appointment, Julphar’s chairman Sheikh Faisal Bin Saqr Al Qasimi said: "I trust de Chazeaux is an established financial executive with extensive background overseeing finance organizations. With him leading the finance team, I am confident that we will be well-positioned to enter the next phase of our strategy execution."

Over the last 20 years, de Chazeaux has worked in a number of senior finance roles in the pharmaceutical industry and in investment banking.

He spent several years working for Cowen, where he was in charge of analyzing performances of midsize European pharmaceutical companies, and before joining Julphar as Associate Director Finance in June 2017, he worked at Sanofi and as Finance Director at AstraZeneca.

A degree holder from EDHEC Business School (France) in International Management, de Chazeaux has been living in the Middle East for the past 10 years.

On his new role, de Chazeaux said: "I am much honoured to have been appointed to this role. I will work closely with the executive team and will focus on driving performance to help the company achieve its next stages of growth."

Established in 1980, Julphar is one of the largest pharmaceutical manufacturers in Middle East and North Africa, producing over 200 branded products across 16 facilities.-TradeArabia News Service